Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Lepidoglyphus destructor.

If you suffer from allergies to dust mites, you'll know how disruptive symptoms like a runny nose, itchy eyes, and sneezing can be. Sometimes these allergies can also lead to mild asthma. This study is exploring a new injection treatment, a type of 'allergy shot' (immunotherapy), designed to help your body become less sensitive to dust mites.

The main aim of this study is to see if this new treatment can significantly reduce the symptoms of dust mite allergy and improve your overall well-being. Researchers will be comparing it to a 'dummy' injection, known as a placebo. This helps them understand whether any improvements are truly due to the active medication or other factors. Both you and your doctor won't know whether you are receiving the active treatment or the placebo, which is a standard way to make sure the results are as fair and accurate as possible.

Throughout the study, you'll be asked to keep a diary to track how your symptoms change over time. The study will also be looking at how the treatment might affect your quality of life, how often you need to use other allergy or asthma relievers, and, importantly, what side effects, if any, you might experience. This information will help doctors understand if this treatment could become a helpful option for people like you in the future.